ArticleOpen veterinary journal2026
Optimization of in-house indirect ELISA for the detection of mice IgG anti-dengue prM/E DENV-3 as a vaccine candidate.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue infection has increased significantly in subtropical and tropical regions in recent decades. As of 2020, 15 countries, including Indonesia, reported increasing cases, with mortality rates of approximately 0.5%-3.5%. Since 2014, the Dengue Vaccine Research Consortium under the Ministry of Health in the Republic of Indonesia has advanced a sharia-compliant dengue vaccine prototype in the form of the premembrane/envelope (prM/E) dengue virus (DENV)-1,-2,-3,-4 recombinant proteins. Aim: This study aims to develop and optimize an in-house indirect enzyme-linked immunosorbent assay (ELISA) for detecting IgG against prM/E DENV-3, serving as a preliminary antibody titer assessment for candidate dengue vaccines and potential diagnostic kits. Methods: Serum samples from mice immunized with 200 ng purified prM/E DENV-3 or 10 Results: Seropositive samples yielded absorbance values exceeding the established cutoff. The statistical analysis showed significant differences between groups ( Conclusion: The optimized in-house ELISA reliably detects IgG responses to recombinant prM/E DENV3, supporting its utility in early-stage evaluation of dengue vaccine candidates and in the development of diagnostic tools. This study is a successful stage supporting the development of prM/E DENV-1,-2,-3,-4 as a candidate dengue vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.